No Data
No Data
Yakkang Biotech (688046.SH): The ban on 2 million restricted shares was lifted on April 25
On April 16, Gelonghui (688046.SH) announced that the total number of shares in circulation in the company's current stock listing is 2 million shares. The stock listing and circulation date is April 25, 2024.
Yakkang Biology (688046.SH): No plans to directly enter the field of gene modification therapy
Gelonghui, April 8, 丨 Yakang Biology (688046.SH) said on the investor interactive platform that gene editing technology, as an underlying technology, can be applied in a wide range of fields. The company is closely monitoring technological progress and industry trends. The company is temporarily focusing on the field of model animals and has no plans to directly enter the field of gene modification treatment.
Yakkang Biotech (688046.SH): spent 238.625 million yuan to buy back a total of 1,522,000 shares
Gelonghui, April 2, 丨 Yakang Biotech (688046.SH) announced that as of March 31, 2024, the company had repurchased 1,522,000 shares of the company's shares through centralized bidding transactions, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 238.625 million (excluding transaction fees such as stamp duty and transaction fees).
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 40.1x GemPharmatech Co., Ltd. (SHSE:688046) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios
Yakkang Biotech (688046.SH): A total cost of 238.267 million yuan to buy back 0.37% of the shares
Gelonghui, March 1, 丨 Yakang Biotech (688046.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,519,302 shares through the Shanghai Stock Exchange trading system, accounting for 0.3706% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 23,826,723.29.
Yakkang Biotech (688046): Performance is in line with expectations, overseas business continues to grow rapidly
Core view: The company released the 2023 annual performance report. In 2023, the company achieved revenue of 622 million yuan (+20.45%, the following are year-on-year values), net profit to mother of 159 million yuan (-3.46%),
No Data